Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

ASCO Clinical Practice Guideline Update Incorporates Oncotype DX

Publish date:: June 13, 2019

Key clinical point: An expert panel has provided new recommendations on the use of Oncotype DX in guiding treatment decisions for women with early-stage invasive breast cancer.

Major finding: In patients with Oncotype DX recurrence scores of less than 26, there is minimal to no benefit from chemotherapy, particularly for those greater than age 50 years.

Study details: A clinical practice guideline update released by the American Society of Clinical Oncology.

Disclosures: The study was funded by ASCO. The authors reported financial affiliations with AstraZeneca, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Roche, and several others.

Citation:

Andre F et al. J Clin Oncol. 2019 May 31. doi: 10.1200/JCO.19.00945.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,